系统性红斑狼疮达标之路:《2019年欧洲抗风湿病联盟系统性红斑狼疮管理指南》解读

2020-05-20 协和医学杂志.2020.11(3):183-188.

《2019 年欧洲抗风湿病联盟系统性红斑狼疮管理指南》是欧洲抗风湿病联盟自2007 年以来,第二次针对系统性红斑狼疮( systemic lupus erthymatosus,SLE) 整体管理制定的

中文标题:

系统性红斑狼疮达标之路:《2019年欧洲抗风湿病联盟系统性红斑狼疮管理指南》解读

发布机构:

发布日期:

2020-05-20

简要介绍:

《2019 年欧洲抗风湿病联盟系统性红斑狼疮管理指南》是欧洲抗风湿病联盟自2007 年以来,第二次针对系统性红斑狼疮( systemic lupus erthymatosus,SLE) 整体管理制定的指南。该指南对SLE 的治疗策略、治疗目标、激素方案选择、狼疮性肾炎“多靶点”治疗以及生物制剂应用等内容进行了更新,在达标治疗的大趋势下,为SLE 如此复杂的疾病,指明了治疗方向。本文对指南更新内容进行详细解读,以期为SLE 临床诊治提供借鉴。

北京大学第一医院风湿免疫科 季兰岚 张卓莉

相关资料下载:
[AttachmentFileName(sort=1, fileName=系统性红斑狼疮达标之路_2019_省略_联盟系统性红斑狼疮管理指南_解读_季兰岚.pdf)] GetToolGuiderByIdResponse(projectId=1, id=fa9db1c0019326cf, title=系统性红斑狼疮达标之路:《2019年欧洲抗风湿病联盟系统性红斑狼疮管理指南》解读, enTitle=, guiderFrom=协和医学杂志.2020.11(3):183-188., authorId=0, author=, summary=《2019 年欧洲抗风湿病联盟系统性红斑狼疮管理指南》是欧洲抗风湿病联盟自2007 年以来,第二次针对系统性红斑狼疮( systemic lupus erthymatosus,SLE) 整体管理制定的, cover=https://img.medsci.cn/2020713/1594645944891_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Wed May 20 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #333333;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>《2019 年欧洲抗风湿病联盟系统性红斑狼疮管理指南》是欧洲抗风湿病联盟自2007 年以来,第二次针对系统性红斑狼疮( systemic lupus erthymatosus,SLE) 整体管理制定的指南。该指南对SLE 的治疗策略、治疗目标、激素方案选择、狼疮性肾炎&ldquo;多靶点&rdquo;治疗以及生物制剂应用等内容进行了更新,在达标治疗的大趋势下,为SLE 如此复杂的疾病,指明了治疗方向。本文对指南更新内容进行详细解读,以期为SLE 临床诊治提供借鉴。</p> <p><label>作者:</label>北京大学第一医院风湿免疫科 季兰岚 张卓莉</p> </div> </div> </div>, tagList=[TagDto(tagId=648, tagName=系统性红斑狼疮)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=648, guiderKeyword=系统性红斑狼疮, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4358, appHits=673, showAppHits=0, pcHits=1137, showPcHits=3684, likes=2, shares=37, comments=21, approvalStatus=1, publishedTime=Mon Jul 13 21:24:10 CST 2020, publishedTimeString=2020-05-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Jul 13 21:12:32 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 21:44:33 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=系统性红斑狼疮达标之路_2019_省略_联盟系统性红斑狼疮管理指南_解读_季兰岚.pdf)])
系统性红斑狼疮达标之路_2019_省略_联盟系统性红斑狼疮管理指南_解读_季兰岚.pdf
下载请点击:
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1240001, encodeId=00791240001d2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200813/13a0125858f94511af5db15e10e86aa8/7eba75c2b28a4fdfba669d681eeada48.jpg, createdBy=51851627871, createdName=lcy0596, createdTime=Sat Aug 20 18:13:21 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238321, encodeId=d6e6123832166, content=提个建议,最好加上原文的链接或者DOI或者PMI号,方便大家读原文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UWQPMeVbLTMYBz42NgpH6acHzzIBsr4Dxk915O6uaicxB8WkRpp6WcKpOOfS07r6958RXtmyNziaD2ETA65ouPCQ/132, createdBy=105c29330, createdName=bobo800101, createdTime=Fri Aug 12 18:16:46 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195247, encodeId=d97b119524e64, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53135119072, createdName=1463018em46暂无昵称, createdTime=Sun Feb 20 00:05:03 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077571, encodeId=4e9310e757176, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211103/0c5e5368ea574291969353a835b71d0f/9e9e98a2e3254bdc806d1750a552dc1e.jpg, createdBy=fb501831399, createdName=明天麻麻, createdTime=Tue Dec 07 00:00:36 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014354, encodeId=044d1014354ee, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc755591863, createdName=ms8000000623347486, createdTime=Fri Sep 03 19:10:27 CST 2021, time=2021-09-03, status=1, ipAttribution=)]
    2022-08-20 lcy0596

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1240001, encodeId=00791240001d2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200813/13a0125858f94511af5db15e10e86aa8/7eba75c2b28a4fdfba669d681eeada48.jpg, createdBy=51851627871, createdName=lcy0596, createdTime=Sat Aug 20 18:13:21 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238321, encodeId=d6e6123832166, content=提个建议,最好加上原文的链接或者DOI或者PMI号,方便大家读原文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UWQPMeVbLTMYBz42NgpH6acHzzIBsr4Dxk915O6uaicxB8WkRpp6WcKpOOfS07r6958RXtmyNziaD2ETA65ouPCQ/132, createdBy=105c29330, createdName=bobo800101, createdTime=Fri Aug 12 18:16:46 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195247, encodeId=d97b119524e64, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53135119072, createdName=1463018em46暂无昵称, createdTime=Sun Feb 20 00:05:03 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077571, encodeId=4e9310e757176, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211103/0c5e5368ea574291969353a835b71d0f/9e9e98a2e3254bdc806d1750a552dc1e.jpg, createdBy=fb501831399, createdName=明天麻麻, createdTime=Tue Dec 07 00:00:36 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014354, encodeId=044d1014354ee, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc755591863, createdName=ms8000000623347486, createdTime=Fri Sep 03 19:10:27 CST 2021, time=2021-09-03, status=1, ipAttribution=)]
    2022-08-12 bobo800101

    提个建议,最好加上原文的链接或者DOI或者PMI号,方便大家读原文

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1240001, encodeId=00791240001d2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200813/13a0125858f94511af5db15e10e86aa8/7eba75c2b28a4fdfba669d681eeada48.jpg, createdBy=51851627871, createdName=lcy0596, createdTime=Sat Aug 20 18:13:21 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238321, encodeId=d6e6123832166, content=提个建议,最好加上原文的链接或者DOI或者PMI号,方便大家读原文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UWQPMeVbLTMYBz42NgpH6acHzzIBsr4Dxk915O6uaicxB8WkRpp6WcKpOOfS07r6958RXtmyNziaD2ETA65ouPCQ/132, createdBy=105c29330, createdName=bobo800101, createdTime=Fri Aug 12 18:16:46 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195247, encodeId=d97b119524e64, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53135119072, createdName=1463018em46暂无昵称, createdTime=Sun Feb 20 00:05:03 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077571, encodeId=4e9310e757176, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211103/0c5e5368ea574291969353a835b71d0f/9e9e98a2e3254bdc806d1750a552dc1e.jpg, createdBy=fb501831399, createdName=明天麻麻, createdTime=Tue Dec 07 00:00:36 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014354, encodeId=044d1014354ee, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc755591863, createdName=ms8000000623347486, createdTime=Fri Sep 03 19:10:27 CST 2021, time=2021-09-03, status=1, ipAttribution=)]
    2022-02-20 1463018em46暂无昵称

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1240001, encodeId=00791240001d2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200813/13a0125858f94511af5db15e10e86aa8/7eba75c2b28a4fdfba669d681eeada48.jpg, createdBy=51851627871, createdName=lcy0596, createdTime=Sat Aug 20 18:13:21 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238321, encodeId=d6e6123832166, content=提个建议,最好加上原文的链接或者DOI或者PMI号,方便大家读原文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UWQPMeVbLTMYBz42NgpH6acHzzIBsr4Dxk915O6uaicxB8WkRpp6WcKpOOfS07r6958RXtmyNziaD2ETA65ouPCQ/132, createdBy=105c29330, createdName=bobo800101, createdTime=Fri Aug 12 18:16:46 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195247, encodeId=d97b119524e64, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53135119072, createdName=1463018em46暂无昵称, createdTime=Sun Feb 20 00:05:03 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077571, encodeId=4e9310e757176, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211103/0c5e5368ea574291969353a835b71d0f/9e9e98a2e3254bdc806d1750a552dc1e.jpg, createdBy=fb501831399, createdName=明天麻麻, createdTime=Tue Dec 07 00:00:36 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014354, encodeId=044d1014354ee, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc755591863, createdName=ms8000000623347486, createdTime=Fri Sep 03 19:10:27 CST 2021, time=2021-09-03, status=1, ipAttribution=)]
    2021-12-07 明天麻麻

    值得学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1240001, encodeId=00791240001d2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200813/13a0125858f94511af5db15e10e86aa8/7eba75c2b28a4fdfba669d681eeada48.jpg, createdBy=51851627871, createdName=lcy0596, createdTime=Sat Aug 20 18:13:21 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238321, encodeId=d6e6123832166, content=提个建议,最好加上原文的链接或者DOI或者PMI号,方便大家读原文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UWQPMeVbLTMYBz42NgpH6acHzzIBsr4Dxk915O6uaicxB8WkRpp6WcKpOOfS07r6958RXtmyNziaD2ETA65ouPCQ/132, createdBy=105c29330, createdName=bobo800101, createdTime=Fri Aug 12 18:16:46 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195247, encodeId=d97b119524e64, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53135119072, createdName=1463018em46暂无昵称, createdTime=Sun Feb 20 00:05:03 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077571, encodeId=4e9310e757176, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211103/0c5e5368ea574291969353a835b71d0f/9e9e98a2e3254bdc806d1750a552dc1e.jpg, createdBy=fb501831399, createdName=明天麻麻, createdTime=Tue Dec 07 00:00:36 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014354, encodeId=044d1014354ee, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc755591863, createdName=ms8000000623347486, createdTime=Fri Sep 03 19:10:27 CST 2021, time=2021-09-03, status=1, ipAttribution=)]
    2021-09-03 ms8000000623347486

    学习

    0

拓展阅读

2010 系统性红斑狼疮诊断及治疗指南

中华医学会风湿病学分会(CRA,Chinese Rheumatology Association) · 2010-05-01

2010 EULAR 治疗有神经精神症状的系统性红斑狼疮患者的推荐意见

欧洲抗风湿病联盟(EULAR,The European League Against Rheumatism) · 2010-12-01

2011 中国儿童系统性红斑狼疮诊疗建议

中华医学会儿科学分会免疫学组 · 2011-07-01

2014 靶向治疗系统性红斑狼疮:国际工作组推荐建议

国外风湿免疫科相关专家小组 · 2014-04-16

2014 糖皮质激素在系统性红斑狼疮患者合理应用的专家共识

中国系统性红斑狼疮研究协作组(CSTAR,Chinese SLE Treatment And Research Group) · 2014-06-03